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232need of prolonged dual antiplatelet therapy with
aspirin and clopidogrel. We agree that the subject is
complex, but physicians should acknowledge that
current guidelines are based on Level of Evidence: C
(2,3). In our opinion, there is no evidence to suggest
that dual antiplatelet therapy is necessary in patients
who receive oral anticoagulation, which itself offers
coronary protection (4). Our registry-based study
and 1 randomized study support the use of
clopidogrel in addition to vitamin K antagonist
(without aspirin) in patients with atrial ﬁbrillation
who are discharged after myocardial infarction or
percutaneous coronary intervention (5). Although
most stents implanted in recent years are drug-
eluting stents, we acknowledge the important
limitation of our data that no information on stent
type was available. However, there is no indication
that stent type should affect the risk of bleeding.
Dr. Aytürk and colleagues wisely highlight that it is
a multifaceted challenge when prescribing
numerous antithrombotic drugs, and we would like
to add to the ongoing and important discussion
that bleeding risk merits serious attention. A
bleeding event, per se, is associated with increased
mortality, blood transfusion is associated with
poorer prognosis, and minor bleedings could result
in discontinuation of life-saving antithrombotic
therapies (6). This is emphasized by the use of
bleeding as a primary endpoint in many contempo-
rary trials of antiplatelet use following stent
implantation.
Until more randomized trial data are available,
careful assessment of bleeding risk and recognizing
current (although sparse) evidence is crucial when
individualizing antithrombotic therapy in patients
with atrial ﬁbrillation who experience an acute
coronary event with or without stent implantation
(7). Due to bleeding complications, interventionists
should carefully consider the need for a drug-
eluting stent compared with a bare-metal stent
and carefully consider the indication for stent
implantation.*Morten Lamberts, MD, PhD
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A Reliable Predictor of Response
to Renal Denervation?We read the paper by Zuern et al. (1), demonstrating
that cardiac baroreﬂex sensitivity (BRS) may predict
the blood pressure (BP) response to renal dener-
vation (RDN) in patients with treatment-resistant
hypertension, with great interest. These ﬁndings
appear to be of major clinical importance if indeed
patient groups that may particularly beneﬁt from
RDN can be identiﬁed. However, there are several
issues that will have to be addressed to fully
understand the relevance of these ﬁndings.
It is surprising that the authors did not measure
BRS function at some stage after RDN, which would
have been important to understand whether or
not RDN actually alters BRS as such and there-
fore provide information on relevant mechanisms
potentially underlying improved BP control after
successful RDN. Furthermore, given that half of the
patients from this study cohort were classiﬁed as
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233“responders,” deﬁned as a reduction in ambulatory
systolic blood pressure (SBP) of >10 mm Hg, it ap-
pears crucial to ascertain whether the BP reduction
following RDN parallels BRS improvement in these
patients. This is even more important in view of
recent ﬁndings demonstrating that baroreﬂex func-
tion consistently improves after RDN in hypertensive
rats and humans, even if BP is not improved (2). In
this context, it is noteworthy that similar to previous
studies (3,4), baseline BP also emerged as an impor-
tant determinant of the BP response to RDN in this
analysis.
The methodology applied by the authors may raise
some concern. In contrast to the commonly used
application of the sequence method for the assess-
ment of BRS described by Parati et al. (5), sponta-
neous sequence of BRS in this study was estimated
only during the progressive increase of SBP over 3 or
more consecutive beats in which RR intervals are
simultaneously prolonged, but not when SBP pro-
gressively falls and cardiac intervals are progressively
shortened. Additionally, assessment of baroreﬂex
control of heart rate is to a large extent driven by
vagal inﬂuences, not necessarily by the sympathetic
nervous system, although the opposite is frequently
quoted in the literature (6). Nevertheless, our own
ﬁndings from more than 100 patients with resistant
hypertension indicate that these patients are typi-
cally characterized by very high levels of muscle
sympathetic nerve activity, with RDN resulting in
sympathetic inhibition in most. In this context, it will
be important to assess whether spontaneous arterial
baroreﬂex control of muscle sympathetic nerve ac-
tivity may be an even better predictor of the BP
response to RDN. It should also be noted that,
although established hypertension is associated with
impaired baroreﬂex function, the role of baroreﬂex
control in long-term regulation of BP is more
disputable and has not yet been fully elucidated.Dagmara Hering, MD, PhD
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Auton Res 2003;13:170–2.REPLY: Baroreﬂex Sensitivity: A Reliable
Predictor of Response to Renal Denervation?We appreciate the interest in our paper (1) and the
opportunity to reply to the thoughtful comments by
Dr. Hering and colleagues.
We agree that testing the effect of renal sympa-
thetic denervation (RDN) on cardiac baroreﬂex
sensitivity (BRS) would provide important insights
into the mechanistic basis of RDN. However, this was
not the objective of our study (1). The primary goal
of our clinical study was to prospectively identify
patients with resistant hypertension who would
eventually beneﬁt from RDN. We showed in 50 hy-
pertensive patients that impaired cardiac BRS was a
strong and independent predictor of blood pressure
(BP) reduction after RDN.
Dr. Hering and colleagues speculated that RDN
should lead to BRS improvement only in patients who
beneﬁt from RDN in terms of BP reduction. Their
interesting hypothesis was on the basis of physio-
logical considerations as well as on a recent study in
7 hypertensive rats and 8 hypertensive human pa-
tients, which investigated the effects of RDN on BP,
muscle sympathetic nerve activity (MSNA), and BRS
(2). In that study, rats consistently showed signiﬁcant
reductions of BP and MSNA as well as improvements
of BRS, whereas in humans, no signiﬁcant effects
